首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL1RN |
| Uniprot No | P18510 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-177aa |
| 氨基酸序列 | RPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVP IEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAF IRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQE DE |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL1RN重组蛋白的3篇经典文献摘要概述：
1. **《Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist》**
- **作者**: Eisenberg, S.P. et al.
- **摘要**: 该研究首次克隆了人类IL1RN基因，并在哺乳动物细胞中重组表达其蛋白，证实其能特异性结合IL-1受体并拮抗IL-1α和IL-1β的炎症信号，为后续治疗应用奠定分子基础。
2. **《Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist》**
- **作者**: Cohen, S.B. et al.
- **摘要**: 临床试验显示，重组IL1RN(商品名Anakinra)显著减轻类风湿性关节炎患者的关节炎症和损伤，验证了其通过抑制IL-1通路缓解自身免疫疾病的疗效。
3. **《Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor》**
- **作者**: Arend, W.P. et al.
- **摘要**: 研究揭示了重组IL1RN蛋白通过竞争性抑制IL-1与受体的结合，阻断下游促炎因子释放的机制，并证明其在体外和动物模型中有效减轻炎症反应。
如需具体文献来源，建议通过PubMed或Web of Science检索上述标题获取全文信息。
Interleukin-1 receptor antagonist (IL-1RA), encoded by the IL1RN gene, is a naturally occurring cytokine inhibitor that modulates the inflammatory response by competitively binding to interleukin-1 receptors (IL-1R1). This prevents the pro-inflammatory cytokines IL-1α and IL-1β from activating downstream signaling pathways, thereby reducing inflammation and tissue damage. Discovered in the 1980s, IL-1RA plays a critical role in balancing the immune system, as dysregulated IL-1 activity is linked to autoimmune diseases, sepsis, and chronic inflammatory conditions.
Recombinant IL-1RA (e.g., anakinra) is produced using genetic engineering techniques, typically in Escherichia coli or mammalian expression systems. The recombinant protein mimics the native human IL-1RA, consisting of 153 amino acids with a molecular weight of approximately 17 kDa. Its short plasma half-life (4-6 hours) necessitates daily administration for therapeutic use.
Clinically, recombinant IL-1RA has been approved for rheumatoid arthritis and neonatal-onset multisystem inflammatory disease (NOMID). It also shows promise in treating gout, type 2 diabetes, and cardiovascular diseases associated with chronic inflammation. Research continues to explore its efficacy in cytokine storm syndromes, including severe COVID-19 complications. Despite its therapeutic benefits, challenges remain in optimizing delivery methods and minimizing side effects like injection-site reactions. Ongoing studies focus on engineered variants with extended half-lives and combination therapies to enhance anti-inflammatory efficacy.
×
